BMS's Opdivo blows Exelixis's Cometriq kidney cancer data out of the water
This article was originally published in Scrip
Just as Exelixis was finally basking in the glow of positive Phase III progression-free survival data for its anticancer Cometriq in renal cell carcinoma, Bristol-Myers Squibb rained on its parade by stopping the CheckMate-025 study early on positive overall survival data with its immuno-oncology giant Opdivo (nivolumab) in the same setting.
You may also be interested in...
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.
Another failed study in Duchenne muscular dystrophy spells the end for edasalonexent and possibly the firm.
Phase II results look good for one of the first-in-class product’s potential indications, C3 glomerulopathy. The product was highlighted late last year as an up-and-coming pipeline asset.